Skip to main content
OpenTrials
Completed

NCT Number: NCT04707911

Social Media Intervention to Stop Nicotine and Cannabis Vaping Among Adolescents

Social media based intervention to support teens in their efforts to quit vaping.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vaping Behavior Chemically-Induced Disorders Mental Disorders Smoking Substance-Related Disorders Tobacco Use Disorder

Age range

13 year–21 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California, San Francisco

San Francisco, California, 94143, United States

About this study

This study is a randomized controlled trial of a social media intervention to support teens in their efforts to quit vaping.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • English literacy
  • Age between 13-21 years
  • Indicate they use social media "most" (>= 4) days per week
  • Have vaped at least once per week in the past 30 days (90 percent of participants)
  • Access to a computer or mobile phone with photo capability to verify abstinence from vaping
  • Indicate they are considering quitting or are interested in quitting with the next 6 months or within the next 30 days
  • Currently reside in California

Exclusion criteria

  • No English literacy
  • Age under 13 or over 21
  • Insufficient social media use (3 or fewer days per week)
  • Have not vaped at least once per week in past 30 days
  • No access to computer or mobile phone with photo capability to verify abstinence from vaping
  • Not considering or interested in quitting vaping in the next 30 days or 6 months;
  • Not a California resident

Treatment and study plan

Social Media Intervention

Behavioral

Social media based intervention using Instagram with up to 3 posts per day for 30 days

Primary outcomes

  1. Point Prevalent Abstinence (PPA) from vaping

    Time frame: 1 month

    7-day point prevalence abstinence (PPA) from all tobacco products will be assessed over the course of the study. Participants reporting no vaping in the past 7 days will be coded as abstinent. Those reporting 7-day abstinence and not using nicotine replacement therapy will be mailed saliva cotinine test kit and saliva tetrahydrocannabinol (THC) test kit for biochemical verification of abstinence.

  2. Point Prevalent Abstinence (PPA) from vaping

    Time frame: 3 months

    7-day point prevalence abstinence (PPA) from all tobacco products will be assessed over the course of the study. Participants reporting no vaping in the past 7 days will be coded as abstinent. Those reporting 7-day abstinence and not using nicotine replacement therapy will be mailed saliva cotinine test kit and saliva tetrahydrocannabinol (THC) test kit for biochemical verification of abstinence.

  3. Point Prevalent Abstinence (PPA) from vaping

    Time frame: 6 months

    7-day point prevalence abstinence (PPA) from all tobacco products will be assessed over the course of the study. Participants reporting no vaping in the past 7 days will be coded as abstinent. Those reporting 7-day abstinence and not using nicotine replacement therapy will be mailed saliva cotinine test kit and saliva tetrahydrocannabinol (THC) test kit for biochemical verification of abstinence.

Secondary outcomes

  1. Change in the number of participants with reduction in vaping

    Time frame: Up to 6 months

    Reduction in vaping is defined as a decline in vaping frequency by 50 percent (%) or more.

  2. Change in the number of vape quit attempts

    Time frame: Up to 6 months

    The number of quit attempts will be recorded at each assessment.

  3. Number of participants with at least 1 quit attempt

    Time frame: Up to 6 months

    The number of participants whom achieved at least one quit attempt during the full assessment time period will be reported.

  4. Change in response on Stages of Change Questionnaire

    Time frame: Up to 6 months

    The participants readiness to quit will be measured using the Stages of Change questionnaire - single item, which asks "Are you seriously thinking of quitting smoking?" Answers range from 'Yes, within the next 30 days', 'Yes, within the next 6 months', and 'No, not thinking of quitting'.

  5. Change in the score on the Thoughts About Abstinence (TAA) Questionnaire

    Time frame: Up to 6 months

    The adapted Thoughts About Abstinence Questionnaire (Hall et al., 1991) is a 3 item self-report questionnaire that measures: 1) desire to quit smoking, 2) expected success at quitting, 3) expected difficulty of quitting on 10-point Likert scales (e.g., 1=no desire to quit/lowest expectation/lowest level of difficulty to 10 = extreme desire to quit/highest expectation of success/highest expected difficulty)

  6. Change in the scores on the Ways of Quitting questionnaire (WOQ)

    Time frame: Up to 6 months

    The WOQ is a 28-item self-report instrument assessing adolescent smoking cessation strategies. For each WOQ item, respondents indicate whether they have used a given strategy (yes/no) and, if used, how helpful it was perceived to be on a five-point Likert-type scale (1= "Not helpful" to 5="Extremely helpful") with regard to several categories: Social support, Seeking assistance, Avoidance, Reduction, Substitution, Medication, Distraction, and Quit all at once (single item).

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • HopeLab Foundation
  • Rescue Agency
  • Tobacco Related Disease Research Program

Registry information

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Jan 13, 2021
Registry last updated
Jun 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.